Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder

Mehdi Ghasemi a, b, c, d, *, Mohammad H. Kazemi a, e, Abolghasem Yoosofi a, f, Abbas Ghasemi c, Pedram Paragomi a, Homayoun Amini a, f, Mohammad H. Afzali a, g

a Department of Psychiatry, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran 13337-95914, Iran
b Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
c Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran
d Robert S. Boas Center for Genomics and Human Genetics, The Feinstein Institute for Medical Research (FIMR), Manhasset, NY, USA
e Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran 13337, Iran
f Université de Toulouse-Le Mirail, Octogone, 5, Allées Antonio Machado, 31058 Toulouse Cedex 9, France
g NeurExpand Brain Center, 1205 York Road, Lutherville, MD 21093, USA

A R T I C L E  I N F O

Article history:
Received 28 May 2013
Received in revised form 5 November 2013
Accepted 5 December 2013
Available online 13 December 2013

Keywords:
Ketamine
Electroconvulsive therapy (ECT)
Major depressive disorder
Antidepressant
NMDA receptor
NMDA receptor antagonist
Hamilton Depression Rating Scale (HDRS)

A B S T R A C T

Accumulating evidence suggests that N-methyl-D-aspartate receptor (NMDAR) antagonists (e.g. ketamine) may exert rapid antidepressant effects in MDD patients. In the present study, we evaluated the rapid antidepressant effects of ketamine compared with the electroconvulsive therapy (ECT) in hospitalized patients with MDD. In this blind, randomized study, 18 patients with DSM-IV MDD were divided into two groups which received either three intravenous infusions of ketamine hydrochloride (0.5 mg/kg over 45 min) or ECT on 3 test days (every 48 h). The primary outcome measure was the Beck Depression Inventory (BDI) and Hamilton Depression Rating Scale (HDRS), which was used to rate overall depressive symptoms at baseline, 24 h after each treatment, 72 h and one week after the last (third) ketamine or ECT. Within 24 h, depressive symptoms significantly improved in subjects receiving the first dose of ketamine compared with ECT group. Compared to baseline level, this improvement remained significant throughout the study. Depressive symptoms after the second dose ketamine was also lower than the second ECT. This study showed that ketamine is as effective as ECT in improving depressive symptoms in MDD patients and have more rapid antidepressant effects compared with the ECT.

© 2013 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Major depressive disorder (MDD) is a severe, heterogeneous, and common medical illness which is associated with enormous morbidity and public health costs. Cost of illness estimates for depression in the USA varies between $12.4 billion per year for the consequences of not treating depression (Patel, 2008). With depression set to become the second largest cause of disability worldwide by 2020, it is important to examine carefully the cost-effectiveness of any new treatment. Although over the past half century the biogenic amine models have provided meaningful links with the clinical phenomena of, and the pharmacological treatments currently employed in, mood disorders, there is still a need to examine the contribution of other systems to the neurobiology and treatment of mood disorders (Berman et al., 1996; Delgado, 2000). This need stems from the fact that monoamine depletion paradigms, for example, failed to find a “final common pathway” for antidepressant efficacy. Current treatments for MDD are only partially effective in many cases and, in some cases, not at all effective. For instance, a large study on 3671 outpatients with MDD demonstrated that only 36% of MDD patients achieved remission following optimized trial of the serotonin selective reuptake inhibitor citalopram for up to 12 weeks (Rush et al., 2006). Furthermore, remission in half of the patients often occurs after 6 months of treatment with two antidepressant trials (Trivedi et al., 2006). Emerging from previous studies is a rapidly changing picture that may provide an entirely new set of potential therapeutic targets. Accumulating data in recent years have demonstrated that the excitatory glutamatergic/NMDA (N-methyl-D-aspartate) receptor signaling may play a pivotal role in the pathophysiology of MDD. This hypothesis has
arisen from many observations by many investigators worldwide. Among NMDA receptor antagonists, ketamine has been investigated in both clinical and pre-clinical studies on mood disorders (for review see Ghasemi, 2013). Both clinical and pre-clinical data have robustly shown that ketamine could exert antidepressant effects and could be a promising drug for rapid improvement of major depression, especially in treatment-resistant MDD patients. Electroconvulsive therapy (ECT) is recognized as a highly beneficial treatment of unipolar and bipolar depression (Kellner et al., 2012). ECT has generally a more rapid onset of action than conventional antidepressants do, but the limited data on the onset of ECT’s antidepressant action suggest that a range of 5–7 treatments (approximately 2 weeks) are required, on average, to cause a significant reduction in symptom severity, varying some by position of lead placement and stimulus intensity (Nobler et al., 1997; Kellner et al., 2012). On the other hand, the antidepressant effect exerted by ketamine in previous preliminary studies is consistently observed within the first few hours of its administration, with response rates ranging from 50% to 90%, 1–3 days after a single injection of ketamine (Aan Het Rot et al., 2012; Ghasemi, 2013). This rapid antidepressant effect is also in contrast to traditional monoamine-based antidepressants that take weeks to months to reach their full antidepressant effect (Katz et al., 2004), with response rates between 40% and 50% (Trivedi et al., 2006). A prospective study (Okamoto et al., 2010) comparing ketamine (0.86 mg/kg) to propofol (0.94 mg/kg) for ECT anesthesia also demonstrated that ketamine is associated with an earlier anti-depressant response during the first 2 weeks of ECT. Although these data has suggested that ketamine can potentiate antidepressant effects of ECT in MDD, the fact that whether ketamine is as effective as ECT in MDD needs to be further investigated. Therefore, the aim of the present study was to investigate the antidepressant effects of ketamine in comparison with ECT in hospitalized MDD patients experiencing a major depressive episode.

2. Materials and methods

2.1. Subjects

Patients aged 18–75 years experiencing a major depressive episode and scheduled to receive ECT treatment and were able to provide voluntary consent were recruited into this study. Participants met criteria for a diagnosis of major depressive disorder (MDD), currently in a major depressive episode, according to DSM-IV (First et al., 1995). All participants provided written informed consent according to the Tehran University of Medical Sciences’ human investigation committee approved study protocol. Exclusion criteria were a lifetime diagnosis of primary psychotic disorder, manic or hypomanic episode, mental retardation, dementia, or mood disorder due to general medical condition. Patients with substance dependence or serious medical conditions (e.g. guilt or feelings of being punished), as well as physical symptoms (e.g. fatigue, weight loss, and lack of interest in sex). When the test is scored, a value of 0–1 is assigned for each answer and then the total score is compared to a key to determine the depression’s severity. Higher total scores indicate more severe depressive symptoms.

2.4. Experts’ ratings of depressive symptoms: Hamilton Depression Rating Scale-25 (HDRS25)

Independent physicians and psychologists assessed patients’ depression severity with the HDRS (Hamilton, 1960). The 25-item questionnaire evaluates symptoms related to depression (e.g. low mood, suicidality, irritability, tension, loss of appetite, loss of interests, and somatic symptoms). When the test is scored, a value of 0–5 is assigned for each answer, with higher total scores reflecting more marked depressive symptoms.

3. Results

3.1. Patients

Eighteen patients diagnosed with major depression were randomized in two groups. Demographic features and baseline depression scores, as well as medication used during and before the current major depressive episode, are summarized in Tables 1 and 2. Patients’ age was ranged between 20 and 74 years with a mean of 37.6 years (S.D. = 15.05). Ten patients in both groups were female (56%). Patients received their first target treatment an average of 12.94 (S.D. = 10.2) days after entering the hospital. Nine (50%) patients were randomized in ketamine group and other 9 (50%) received the ECT. Comparison of demographic features and baseline depression scores did not show a significant difference between two groups.

3.2. Efficacy

After Greenhouse–Geisser correction the linear mixed model showed a significant improvement in depression scores evaluated by BDI ($F_{(8,80)} = 50.56, P < 0.001$) and HDRS ($F_{(8,80)} = 73.7, P < 0.001$).
دریافت فوری
متن کامل مقاله

امکان دانلود نسخه تمام متن مقالات انگلیسی
امکان دانلود نسخه ترجمه شده مقالات
پذیرش سفارش ترجمه تخصصی
امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
امکان دانلود رایگان ۲ صفحه اول هر مقاله
امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
دانلود فوری مقاله پس از پرداخت آنلاین
پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات